Abstract
P-TYRAMINE is a normal constituent of human urine1–8, excreted in free and conjugated forms2,4,8. The level of excretion is quantitatively evaluated by separating the phenolicamine fraction (isolated by absorption onto a ‘Biorad AG50W-X2’ column1) overnight in isopropylether: methylethyl ketone : acetic acid : water 9 : 1 : 5 : 5 (v/v) on a Whatman No. 2 paper strip followed by conversion to the 1-nitroso-2-naphthol fluorophore and photodensitometric evaluation9. This procedure has shown that approximately 60% of Parkinson patients excrete more unconjugated urinary p-tyramine than does a control group4,8,10. Food precursors rich in p-tyramine were shown to increase the levels of conjugated p-tyramine and its principal acid metabolite p-hydroxyphenylacetic acid (both free and bound forms)4,8,11. These three metabolites increased so as to account almost stoichometrically for the ingested amine4. Sterilization of the intestinal tract with neomycin and succinyl sulphathiazole in a patient with Parkinson's disease caused a considerable increase in both free and bound forms of both amine and acid4. These findings suggest that a proportion of conjugated p-tyramine and total p-hydroxyphenylacetic acid arise from exogenous sources whereas most of the free urinary p-tyramine is endogenous8. This observation is confirmed in the work of several others5–7 although Perry et al.7 interpret their findings differently. A more convincing demonstration of the validity of our hypothesis followed from an assessment of the urinary free and bound p-tyramine and p-hydroxyphenylacetic acid excreted in urine after oral and intravenous administration of p-hydroxyphenyl(ethylamine-2-14C)-hydrochloride. In a control population only a tiny proportion of ingested p-tyramine, even when substantially supplemented with cold amine, is excreted in the urine in the free form (Table 1). After intravenous injection, however, a variable but significant amount of unconjugated amine is excreted.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kakimoto, Y., and Armstrong, M. D., J. Biol. Chem., 237, 208 (1962).
Boulton, A. A., Pollitt, R. J., and Majer, J. R., Nature, 215, 132 (1967).
Smith, I., and Kellow, A. H., Nature, 221, 1261 (1969).
Boulton, A. A., Prog. Neurogenetics, 1, 437 (1967).
Asatoor, A. M., Clin. Chim. Acta, 22, 223 (1968).
DeQuattro, V. L., and Sjoerdsma, A., Clin. Chim. Acta, 16, 227 (1967).
Perry, T. L., Hestrin, M., MacDougall, L., and Hansen, S., Clin. Chim. Acta, 14, 116 (1966).
Boulton, A. A., Marjerrison, G. L., and Majer, J. R., Symp. Clin. Biol. Res. Schizophrenia, Leningard (September 1970 in the press).
Boulton, A. A., Meth. Biochem. Anal., 16, 327 (1968).
Marjerrison, G. L., Boulton, A. A., and Rajput, A., Intern. J. Clin. Pharmacol., 4, 263 (1971).
Boulton, A. A., in L-Dopa and Parkinsonism (edit. by Barbeau, A., and McDowell, F. H.) (F. A. Davis, Philadelphia, 1970).
Barbeau, A., Murphy, G. F., and Sourkes, T. L., Science, 133, 1706 (1961).
Horneykiewicz, O., Pharmacol. Rev., 18, 925 (1966).
Cotzias, G. C., in L-Dopa and Parkinsonism (edit. by Barbeau, A., and McDowell, F. H.) (F. A. Davis, Philadelphia, 1970).
Goldstein, L., Sugerman, A. A., Stolberg, H., Murphree, H. B., and Pfeiffer, C. C., EEG Clin. Neurophysiol., 19, 350 (1965).
Marjerrison, G. L., Krause, A. E., and Keogh, R. P., EEG Clin. Neurophysiol., 24, 35 (1968).
Yahr, M. D., Duvoisin, R. C., Schear, M. J., Barrett, R. E., and Hoehn, M. M., Arch. Neurol., 21, 343 (1969).
Christenson, J. G., Pairman, W., and Udenfriend, S., Arch. Biochem. Biophys., 141, 356 (1970).
Boulton, A. A., and Quan, Lillian, Canad. J. Biochem., 48, 1287 (1970).
Sourkes, T. L., Nature, 229, 413 (1971).
Fellman, J. H., and Roth, E. S., Biochemistry., 10, 408 (1971).
Boulton, A. A., and Majer, J. R., Nature, 225, 658 (1970).
Majer, J. R., and Boulton, A. A., J. Chromatog., 48, 322 (1970).
Boulton, A. A., and Majer, J. R., Methods in Neurochemistry, 1, (edit. by Rodnight, R., and Marks, N.) (Plenum, New York, in the press).
Majer, J. R., and Boulton, A. A., Meth. Biochem. Anal., 49, 993 (1971).
Boulton, A. A., and Majer, J. R., Canad. J. Biochem. (in the press).
Sandler, M., Karoum, F., Ruthven, C. R. J., and Calne, D. B., Science, 166, 1417 (1969).
Sandler, M., Goodwin, B. L., Ruthven, C. R. J., and Calne, D. B., Nature, 229, 414 (1971).
Udenfriend, S., in Fluorescence Assay in Biology and Medicine, 164 (Academic Press, New York, 1962).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
BOULTON, A., MARJERRISON, G. Effect of L-Dopa Therapy on Urinary p-Tyramine Excretion and EEG Changes in Parkinson's Disease. Nature 236, 76–78 (1972). https://doi.org/10.1038/236076a0
Received:
Revised:
Issue date:
DOI: https://doi.org/10.1038/236076a0
This article is cited by
-
Tryptamine: A metabolite of tryptophan implicated in various neuropsychiatric disorders
Metabolic Brain Disease (1993)
-
Cerebral decarboxylation ofmeta- andpara-tyrosine
Experientia (1983)


